282 related articles for article (PubMed ID: 27031852)
1. The clinical implications of gene mutations in chronic lymphocytic leukaemia.
Rossi D; Gaidano G
Br J Cancer; 2016 Apr; 114(8):849-54. PubMed ID: 27031852
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
Quijada-Álamo M; Pérez-Carretero C; Hernández-Sánchez M; Rodríguez-Vicente AE; Herrero AB; Hernández-Sánchez JM; Martín-Izquierdo M; Santos-Mínguez S; Del Rey M; González T; Rubio-Martínez A; García de Coca A; Dávila-Valls J; Hernández-Rivas JÁ; Parker H; Strefford JC; Benito R; Ordóñez JL; Hernández-Rivas JM
Clin Transl Med; 2021 Feb; 11(2):e304. PubMed ID: 33634999
[TBL] [Abstract][Full Text] [Related]
3. Relevance of TP53 for CLL diagnostics.
Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
[No Abstract] [Full Text] [Related]
4. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
5. An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.
Worrillow L; Baskaran P; Care MA; Varghese A; Munir T; Evans PA; O'Connor SJ; Rawstron A; Hazelwood L; Tooze RM; Hillmen P; Newton DJ
Oncogene; 2016 Oct; 35(40):5328-5336. PubMed ID: 27041575
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.
De Luca G; Cerruti G; Lastraioli S; Conte R; Ibatici A; Di Felice N; Morabito F; Monti P; Fronza G; Matis S; Colombo M; Fabris S; Ciarrocchi A; Neri A; Menichini P; Ferrarini M; Nozza P; Fais F; Cutrona G; Dono M
Hematol Oncol; 2022 Dec; 40(5):962-975. PubMed ID: 35961859
[TBL] [Abstract][Full Text] [Related]
7. Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
Chin-Yee B; Sadikovic B; Chin-Yee IH
Br J Haematol; 2020 Mar; 188(5):652-660. PubMed ID: 30836431
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
Rossi D; Khiabanian H; Spina V; Ciardullo C; Bruscaggin A; Famà R; Rasi S; Monti S; Deambrogi C; De Paoli L; Wang J; Gattei V; Guarini A; Foà R; Rabadan R; Gaidano G
Blood; 2014 Apr; 123(14):2139-47. PubMed ID: 24501221
[TBL] [Abstract][Full Text] [Related]
9. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
Lionetti M; Fabris S; Cutrona G; Agnelli L; Ciardullo C; Matis S; Ciceri G; Colombo M; Maura F; Mosca L; Gentile M; Recchia AG; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Rossi D; Gaidano G; Morabito F; Ferrarini M; Neri A
Br J Haematol; 2014 Jun; 165(5):629-39. PubMed ID: 24579978
[TBL] [Abstract][Full Text] [Related]
10. Detection and Functional Analysis of TP53 Mutations in CLL.
Pavlova S; Smardova J; Tom N; Trbusek M
Methods Mol Biol; 2019; 1881():63-81. PubMed ID: 30350198
[TBL] [Abstract][Full Text] [Related]
11. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
12. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
13. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.
Yu L; Kim HT; Kasar S; Benien P; Du W; Hoang K; Aw A; Tesar B; Improgo R; Fernandes S; Radhakrishnan S; Klitgaard J; Lee C; Getz G; Setlur SR; Brown JR
Clin Cancer Res; 2017 Feb; 23(3):735-745. PubMed ID: 27503198
[TBL] [Abstract][Full Text] [Related]
14. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21).
Burlet B; Ramla S; Fournier C; Abrey-Recalde MJ; Sauter C; Chrétien ML; Rossi C; Duffourd Y; Ragot S; Buriller C; Tournier B; Chapusot C; Nadal N; Racine J; Guy J; Bailly F; Martin L; Casasnovas O; Bastie JN; Caillot D; Albuisson J; Broccardo C; Thieblemont C; Delva L; Maynadié M; Aucagne R; Callanan MB
Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608382
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications.
Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Hernández-Sánchez JM; Vidal MJ; de Coca AG; Aguilar C; Vargas-Pabón M; Alonso S; Sierra M; Rubio-Martínez A; Dávila J; Díaz-Valdés JR; Queizán JA; Hernández-Rivas JÁ; Benito R; Rodríguez-Vicente AE; Hernández-Rivas JM
Int J Cancer; 2020 Nov; 147(10):2780-2792. PubMed ID: 32720348
[TBL] [Abstract][Full Text] [Related]
18. Frequency Of TP53 Gene Mutation In Patients With Chronic Lymphocytic Leukaemia.
Qadir H; Nasir N; Qadir N; Adil SN; Tanzeem H; Qadir A
J Ayub Med Coll Abbottabad; 2020; 32(4):523-526. PubMed ID: 33225656
[TBL] [Abstract][Full Text] [Related]
19. Present and future of personalized medicine in CLL.
Montserrat E; Bauman T; Delgado J
Best Pract Res Clin Haematol; 2016 Mar; 29(1):100-110. PubMed ID: 27742064
[TBL] [Abstract][Full Text] [Related]
20.
Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
